Cardiff, UK –3 November 2014 – EKF Diagnostics, the global diagnostics company, announces that it will be introducing two new diagnostic tests at Medica 2014, 12-15th November, Düsseldorf, Germany. In Hall 3 on Stand C70, visitors can see EKF’s novel assay for early sepsis detection, as well its new hand-held point of care hemoglobin analyzer. Alongside these new products, EKF will also be exhibiting a new version of its Hemo Control hemoglobin analyzer, the industry-leading Biosen glucose and lactate analyzer, as well as previewing SensPoint, a new lactate analyzer designed for use in professional medical settings.
Identify sepsis earlier
The new CE marked Liquicolor® Procalcitonin liquid-stable assay can be used on most automatic chemistry analyzers as an early and specific indicator of sepsis. Since Procalcitonin (PCT) levels elevate during systemic bacterial infection and sepsis, PCT can be used to quickly assess initial severity of sepsis.
The new Liquicolor PCT immunoturbidimetric assay is precise, convenient and cost effective as it is available in a liquid-stable format, which can remain stable on-board a clinical chemistry analyzer for up to four weeks, and requires a minimal sample of just 20 µL. This assay can also improve laboratory workflow as it can be run on a primary chemistry analyzer and eliminate the need to split a sample. The reagent kit, calibrator and control sets are all available separately.
Immediate hemoglobin results
EKF Diagnostics will also be showcasing the new DiaSpect Tm hemoglobin analyzer. This palm-sized point of care analyzer is fast, easy to use and reliable in all climate conditions since it combines laboratory quality performance with unmatched measurement speed and extensive battery life.
In addition to its accuracy of result, DiaSpect Tm is extremely robust since it has no moving parts. Furthermore it utilizes reagent-free microcuvettes which are unaffected by humidity, unlike reagent-based systems. These plexiglass microcuvettes also have a long shelf-life of 2.5 years with no need for refrigeration as they can be stored from 0° to 50°C. DiaSpect Tm is portable and lightweight at just 185g and has an extremely long battery life of 40 days of continuous use, or 10,000 tests, due to its integrated rechargeable lithium-ion battery.
DiaSpect Tm is factory calibrated against the HiCN reference method in accordance with ICSH and requires no re-calibration or maintenance, as it undertakes an automatic self-check between every measurement. Its ‘always on’ technology also means the analyzer is permanently ready for use. The user simply collects a capillary or venous blood sample of <10 µL in the microcuvette and inserts it directly into the analyzer. Hemoglobin results are delivered in just one second which can then be downloaded to a PC via USB or Bluetooth.
For more information on Procalcitonin, the DiaSpect Tm hemoglobin analyzer or EKF Diagnostics, please visit www.ekfdiagnostics.com.
About EKF Diagnostics
EKF Diagnostics Holdings plc, which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, DiaSpect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new molecular division, EKF Molecular Diagnostics, focuses on technology used within the development of companion diagnostics, specifically within oncology. EKF products are sold in more than 100 countries around the globe, through a network of specialist distributors.
Point-of-care diagnostics: EKF Diagnostics designs and manufactures world-class diagnostic devices, as well as distributing rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.
Central laboratory: EKF, through its wholly owned subsidiary, Stanbio Laboratory (Boerne, Texas, USA), manufactures a comprehensive range of clinical chemistry reagents. In addition, EKF Life Sciences (Elkhart, Indiana, USA) manufactures enzymes used in reagent development and also provides contract fermentation facilities.
Molecular Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics following the acquisition of UK-based 360 Genomics. EKF Molecular Diagnostics’ technology, PointMan, is capable of detecting mutant genes from tiny biopsy and blood samples and has recently entered a partnership with the world renowned cancer research center at Massachusetts General Hospital, USA.
EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.